RightFit
RecruitingNot applicable

CommunityRx-Dementia + Peer Navigation (CRxDpeer)

CommunityRx-Dementia + Peer Navigation (CRxDpeer): A Real-World Implementation and Effectiveness Study of an IT-Based Social Care Intervention

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years and older
Sex
All sexes
Healthy volunteers
Accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests support from a trained peer mentor for caregivers of people with Alzheimer's disease or related dementias who live at home. Caregivers get information about care needs, a list of local resources, and help connecting with services and support. The program includes text messages and ongoing mentor support for 12 months.

The CRxDpeer intervention, delivered by a trained peer navigator, in practice called a "peer mentor", includes three evidence-based components: (a) focused education about common social (e.g., food and housing insecurity) and caregiving (e.g., respite and end of life care) needs, (b) activation of personalized community resource information for social and caregiving needs through delivery of a resource list (HealtheRx) at the baseline encounter and coaching on how to communicate with service providers, coordinate services and manage social support (e.g., connect with their peer navigator, reach out to friends or relatives for support, identify support groups, etc.) and (c) ongoing navigation-focused support meant to boost the baseline intervention, including a series of proactive text messages over 12 months. During this time, the subject can respond to and communicate with the peer navigator for ongoing support.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Identify yourself as a caregiver for someone with Alzheimer's disease or a related dementia who lives at home.
  • Live in the area covered by the study.
  • Have access to a cell phone and agree to get study text messages.
  • Have an email address where you can receive emails.
  • If under age 18, be legally recognized as independent from your parents or guardians in Illinois and care for someone with dementia.

Who can't join

  • Be under age 18 and not legally recognized as independent from your parents or guardians in Illinois.
  • Have already been in the group that received the program in the CommunityRx-Dementia clinical trial.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Self-identifies as a caregiver of a home-dwelling person with Alzheimer's disease or related dementias (ADRD) * Resides in the target geographic region of the study * Has access to a cell phone and agrees to receive text messages from the study * Has an email address that they can receive emails from * Individuals under the age of 18 who are emancipated minors in the state of Illinois and a caregiver of a person with dementia Exclusion Criteria: * Minors who are not emancipated in the state of Illinois. * Previously participated in the intervention arm of the CommunityRx-Dementia clinical trial

Study sites (1)

IL